Skip to content
  • CONTACT US
  • CAREERS
  • Share
Allogene Logo
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY AND INCLUSION
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY AND INCLUSION
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY

SC 13G: A statement of beneficial ownership of common stock by certain persons

  • Post author:andrewkaretas
  • Post published:February 3, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

You Might Also Like

4: Statement of changes in beneficial ownership of securities

January 18, 2023

8-K: Report of unscheduled material events or corporate event

February 28, 2023

4: Statement of changes in beneficial ownership of securities

March 16, 2023

Recent Posts

  • 4: Statement of changes in beneficial ownership of securities
  • 4: Statement of changes in beneficial ownership of securities
  • 4: Statement of changes in beneficial ownership of securities
  • 4: Statement of changes in beneficial ownership of securities
  • Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

Recent Comments

No comments to show.
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity and Inclusion
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts
Facebook
Twitter
LinkedIn
E-Mail
Tumblr
Reddit
WhatsApp
Telegram
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity and Inclusion
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY POLICY